HOME | 中文 | ENGLISH
Home
About Us
Wuxi Beita
Changsha Beita
Cooperation Units
Intellectual Property
Academic Publications
Qualification
Products
Radioisotope Labeled Products
Stable Isotope Labeled Products
Services
Technology Advantages
Labeling Service
Detection and Analysis Services
Customers
News
Beita News
Industry News
Media Coverage
Contact Us
Feedback
Information List
Congratulations to Wuxi Beta for Providing SH-1028 New Drug of Shenghe Pharmaceutical Co., Ltd. with Carbon 14 Isotope Labeling Service
2019-08-01
Congratulations to Wuxi Beta for providing the Koren Pharmaceutical KL060332 Capsule labeled with carbon 14 isotope, which has been accepted by the National Food and Drug Administration Clinical Trial Notice and FDA Drug Clinical Trial Application
2019-07-31
On July 25, 2019, Sichuan Kelun Pharmaceutical Co., Ltd., an A- share listed company, issued the notice on the company's KL060332 capsule obtaining clinical trial notice and the acceptance of SKB264 new drug clinical trial application. The innovative drug KL060332 capsule developed by the company's holding subsidiary Sichuan Kelun Botai Biopharmaceutical Co., Ltd. has obtained the clinical trial notice of the State Drug Administration, and the KLUSPharmaInc of the company's holding subsidiary. Has been submitted to the United States Food and Drug Administration (hereinafter referred to as FDA) antibody conjugate drugs (AntibodyD
Good news! The Party Branch of Wuxi Beta Pharmaceutical Technology Co., Ltd. was approved to be established.
2019-07-26
Recently, the Party Working Committee of Jiangyin High-tech Zone approved the establishment of the Party branch of Wuxi Beta Pharmaceutical Technology Co., Ltd., which is a major event and happy event in the history of the company's entrepreneurial development. Since then, Wuxi Beta has an excellent grasp and position for team building. In the next step, the Party branch of Wuxi Beta Pharmaceutical Technology Co., Ltd. will follow the "Articles of the Communist Party of China", "Regulations on the Work of the Communist Party of China (Trial)", and "Opinions of the Organization Department of the Jiangyin Municipal Committee of the Communist Party of China on Promoting the Construction of the" Jiyanghong "Pioneer Position Demonstration Project", "Jiangyin High-tech Zone" Two New "Organization Party Building Work Tackling Tackling Quality and Quality Action Plan" and other party regulations and policy documents, in
Wuxi Beta Won the Second Prize of China Jiangyin (High-tech Zone) Innovation and Entrepreneurship Competition in 2019
2019-06-17
In order to implement the innovation-driven development strategy, further promote "mass entrepreneurship and innovation", continuously expand the characteristic industries of the high-tech zone, accelerate the cultivation of innovative industrial clusters, continue to create an environment for innovation and entrepreneurship, and stimulate the vitality of innovation and entrepreneurship in the region, since May this year, Jiangyin Science and Technology and Talent work leading Group and Jiangyin National High-tech Zone jointly held the 2019 China Jiangyin (High-tech Zone) Innovation and Entrepreneurship Competition with the theme of Zhihui Jiangyin, the competition attracted more than 200 enterprises and teams from Beijing, Shanghai, Guangzhou, Shenzhen, Nanjing, Wuhan, Suzhou, Wuxi and other places. Wuxi Beta
Jiangsu Federation of Industry and Commerce-Wuxi Beta: Focus on Research and Development of "Carp into Dragon"
2019-04-15
Wuxi Beta: Focus on Research and Development of "Carp into Dragon" Source: Jiangyin Federation of Industry and Commerce Date: 2019-03-01 Website: http://www.jssh.org.cn/xxjlpt/sbxt/wxs/201903/t20190301_175211.html近日,位于江阴生物医药加速器的无锡贝塔医药科技有限公司与科伦药业子公司四川科伦药物研究院签订科技服务合作协议 。 Radioisotope labeling of Wuxi Beta by the head of the new drug research and development department of Sichuan Kelun Pharmaceutical Research Institute
Jiangyin Daily Digital News Platform-Wuxi Beta: Focus on Research and Development of "Translating Carp into Dragon"
Wuxi Beta: Focus on Research and Development of "Carp into Dragon" Reporter Liu Xiao Website: http://cnepaper.com/jyrbszb/html/2019-03/01/content_5_1.htm近日,位于江阴生物医药加速器的无锡贝塔医药科技有限公司与科伦药业子公司四川科伦药物研究院签订科技服务合作协议 。 The head of the new drug research and development department of Sichuan Kelun Pharmaceutical Research Institute recognized Wuxi Beta's radioisotope labeling work and believed that Wuxi Beta was the Sichuan Kelun Pharmaceutical Research Institute in 2018.
Carbon -14 Marked Key Compound Preparation Technology Difficulties Overcome-China High-tech Network-China High-tech Industry Guide.
Technical Difficulties in Preparation of Carbon -14 Marked Key Compounds Overcome 2019-03-2210:57:59 Source: Science and Technology Daily Author: Guo Guozhong Shen Wei Guo Yin Qingxi Website; http://www.chinahightech.com/html/yuanqu/yqcy/2019/0322/518171.html3月20日,江苏省江阴国家高新区发布了一项重点创新成果:该区无锡贝塔医药科技有限公司研发团队经过10年努力,攻克了碳-14标记关键化合物制备和标
C14 Marked Key Compound Preparation Technology Conquer-China Chemical News (Sinochem New Net)
C14 Marked Key Compound Preparation Technology Conquer Author: Wu Ban Source: China Chemical News March 26, 2019 Website; http://www.ccin.com.cn/detail/c18866c562abbac1ba4154d0ca9e214c/news中化新网讯3月20日,江苏省江阴国家高新区发布了一项重点创新成果:该区无锡贝塔医药科技有限公司攻克了C14标记关键化合物制备和标记技术,成功开发出用于胃幽门螺旋杆菌感染诊断
Overcome the technical difficulties in the preparation of carbon -14 labeled key compounds-Economic Daily, China Economic Net
Technical Difficulties in Preparation of Carbon -14 Marked Key Compounds Overcome 2019-03-2109:31 Source: Science and Technology Daily Website: http://tech.ce.cn/news/201903/21/t20190321_31719326.shtml
China Overcomes Technical Difficulties in Preparation and Labeling of Key Carbon -14 Labeling Compounds_Sohu Net-News
Website: http://www.sohu.com/a/302811457_115479我国攻克碳-14标记关键化合物制备与标记技术难关科技日报3月20日消息,3月20日,江苏省江阴国家高新区发布了一项重点创新成果:该区无锡贝塔医药科技有限公司研发团队经过10年努力,攻克了碳-14标记关键化合物制备和标记技术难关,并集成应用多项现代先进技术,成功开发出用于胃幽门螺旋杆菌感染诊断用的关键紧缺原料药尿素-
● Beita News
● Industry News
● Media Coverage